CGP52411

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

CGP52411 (DAPH) is a highly selective, orally active, and ATP-competitive EGFR inhibitor (IC50: 0.3 μM).

CGP52411 (DAPH) is a highly selective, orally active, and ATP-competitive EGFR inhibitor (IC50: 0.3 μM). It blocks the toxic influx of Ca2+ ions into neuronal cells and dramatically inhibits and reverses the formation of β-amyloid (Aβ42) fibril aggregates.(In Vitro):In A431 cells, CGP52411 (0-100 μM) dose-dependently inhibits autophosphorylation and c-src autophosphorylation with IC50s of 1 μM and 16 μM, respectively. CGP52411 reduces tyrosine phosphorylation of p185c-erbB2 in a concentration-dependent manner(IC50 = 10 μM).CGP52411 inhibits c-src kinase (IC50 = 16 μM) and PKC isozymes isolated from porcine brain (IC50 = 80 μM).(In Vivo):In female BALB/c nude mice, CGP52411 (6.3 mg/kg-50 mg/kg; orally) shows antitumor efficacy.

DAPH

Others

Other Targets

Non-cleavable

——

——

145915-58-8

329.4

C20H15N3O2

>98% (HPLC)

——

O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12

——

(-20℃)

With Ice Pack

≥ 2 years